GAMA
CLVS

Graticule Asia Macro Advisors’s Clovis Oncology, Inc. CLVS Stock Holding History

Graticule Asia Macro Advisors’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-15,000
Closed -$1.4M – 134
2017
Q2 		$1.4M Buy
+15,000
New +$918K 0.07% 96

Other funds holding CLVS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Graticule Asia Macro Advisors's CLVS Position: Q4 2017 in Review

Graticule Asia Macro Advisors sold out of Clovis Oncology, Inc. (CLVS) in Q4 2017, closing a stake of 27,700 shares — an estimated $2.28M sold.

Graticule Asia Macro Advisors first reported a position in CLVS in Q3 2016 and held it in 5 quarters. The position peaked at $8.59M in Q1 2017. 247 funds tracked by Wall St. Rank hold CLVS as of Q4 2017.

  • Graticule Asia Macro Advisors reported no remaining Clovis Oncology, Inc. position as of Q4 2017 after selling out during the quarter.
  • Graticule Asia Macro Advisors sold 27,700 Clovis Oncology, Inc. shares in Q4 2017, an estimated $2.28M.
  • Graticule Asia Macro Advisors first reported a position in Clovis Oncology, Inc. in Q3 2016 and held it in 5 quarters.
  • Graticule Asia Macro Advisors's Clovis Oncology, Inc. position peaked at $8.59M in Q1 2017.
  • 247 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2017.

Based on Graticule Asia Macro Advisors's 13F filing for Q4 2017, filed 14 Feb 2018.